DK1001792T3 - Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser - Google Patents

Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Info

Publication number
DK1001792T3
DK1001792T3 DK98937862T DK98937862T DK1001792T3 DK 1001792 T3 DK1001792 T3 DK 1001792T3 DK 98937862 T DK98937862 T DK 98937862T DK 98937862 T DK98937862 T DK 98937862T DK 1001792 T3 DK1001792 T3 DK 1001792T3
Authority
DK
Denmark
Prior art keywords
physiologically acceptable
complexes
salts
vanadium compounds
acceptable vanadium
Prior art date
Application number
DK98937862T
Other languages
Danish (da)
English (en)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Application granted granted Critical
Publication of DK1001792T3 publication Critical patent/DK1001792T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98937862T 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser DK1001792T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (fr) 1997-07-29 1998-07-29 Utilisation de composes, de sels et de complexes de vanadium acceptables sur le plan physiologique

Publications (1)

Publication Number Publication Date
DK1001792T3 true DK1001792T3 (da) 2004-01-19

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937862T DK1001792T3 (da) 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser

Country Status (22)

Country Link
US (2) US6579540B1 (fr)
EP (1) EP1001792B1 (fr)
JP (1) JP2001511454A (fr)
CN (1) CN1104244C (fr)
AT (1) ATE253373T1 (fr)
AU (1) AU738701B2 (fr)
BR (1) BR9811298A (fr)
CA (1) CA2298645C (fr)
CZ (1) CZ299716B6 (fr)
DE (1) DE69819514T2 (fr)
DK (1) DK1001792T3 (fr)
EA (1) EA002574B1 (fr)
ES (1) ES2207851T3 (fr)
ID (1) ID24870A (fr)
IL (2) IL134259A0 (fr)
NL (1) NL1006681C2 (fr)
NO (1) NO20000446L (fr)
NZ (1) NZ502613A (fr)
PL (1) PL338415A1 (fr)
PT (1) PT1001792E (fr)
TR (1) TR200000349T2 (fr)
WO (1) WO1999006056A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
WO2001045716A1 (fr) * 1999-12-20 2001-06-28 Gho'st Holding B.V. Composition pharmaceutique comprenant un compose, un sel ou un complexe de vanadium, acceptable au plan physiologique, et un inhibiteur d'echange na?+/h+¿
WO2003041703A2 (fr) * 2001-11-16 2003-05-22 Gho Holding B.V. Methode de traitement des brulures
ES2485384T3 (es) 2007-01-31 2014-08-13 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y/o mayor resistencia al estrés abiótico y un procedimiento para fabricar las mismas
EP2228386B1 (fr) 2007-05-03 2015-03-18 BASF Plant Science GmbH Installations dotées de caractéristiques de rendement améliorées et procédé de fabrication de celles-ci
AU2008280152B2 (en) 2007-07-20 2013-11-21 Basf Plant Science Gmbh Plants having increased yield-related traits and a method for making the same
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
CN102936605A (zh) 2007-10-29 2013-02-20 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物和用于制备该植物的方法
AU2009243552A1 (en) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
EP2648718B1 (fr) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Dispositifs implantables revêtus de composites d'agent mimétique de l'insuline, et procédés associés
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
CA2829259C (fr) * 2011-03-07 2020-02-25 Cfm Pharma Holding Bv Utilisation de composes de pour maintenir la normoglycemie chez un mammifere
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
CN1270525A (zh) 2000-10-18
EA200000176A1 (ru) 2000-10-30
TR200000349T2 (tr) 2000-09-21
AU8650598A (en) 1999-02-22
NO20000446D0 (no) 2000-01-28
US20030211170A1 (en) 2003-11-13
DE69819514T2 (de) 2004-09-23
EP1001792B1 (fr) 2003-11-05
NL1006681C2 (nl) 1999-02-08
ATE253373T1 (de) 2003-11-15
WO1999006056A1 (fr) 1999-02-11
BR9811298A (pt) 2000-08-29
EP1001792A1 (fr) 2000-05-24
CA2298645A1 (fr) 1999-02-11
AU738701B2 (en) 2001-09-27
US6579540B1 (en) 2003-06-17
CZ299716B6 (cs) 2008-10-29
DE69819514D1 (de) 2003-12-11
NO20000446L (no) 2000-03-24
NZ502613A (en) 2001-08-31
CN1104244C (zh) 2003-04-02
ID24870A (id) 2000-08-31
IL134259A0 (en) 2001-04-30
IL134259A (en) 2010-02-17
PL338415A1 (en) 2000-11-06
CA2298645C (fr) 2004-05-18
PT1001792E (pt) 2004-03-31
ES2207851T3 (es) 2004-06-01
EA002574B1 (ru) 2002-06-27
CZ2000326A3 (cs) 2000-07-12
JP2001511454A (ja) 2001-08-14

Similar Documents

Publication Publication Date Title
DK1001792T3 (da) Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
BR0109703A (pt) Derivados de piperazina
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
WO1995031985A3 (fr) Compositions pharmaceutiques contenant un antagoniste des opiaces et des sels de calcium, et leur utilisation dans le traitement de pathologies a mediation endorphinique
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
SE9802208D0 (sv) Novel compounds
NO990833L (no) Farmas°ytiske forbindelser
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ES2128043T3 (es) Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral.
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
SE9802209D0 (sv) Novel compounds
CA2289017A1 (fr) Utilisation d'oxydes d'azote ou de promedicament a base de ces oxydes pour la prevention et le traitement therapeutique du cancer
CA2385755A1 (fr) Prevention du cancer colorectal
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
WO2001016096A3 (fr) Utilisation de bisulfonamides pour preparer des medicaments s'utilisant pour assurer la prophylaxie ou le traitement de l'hyperlipidemie
BR0115911A (pt) Uso de pirazolo[4,3-d]pirimidinas
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler